

## References

I-37

1. Simon E, Ghosh S, Lacucci M, et al. Ustekinumab for the treatment of Crohn's disease: can it find its niche? *Therap Adv Gastroenterol.* 2016;9(1):26-36.
2. Chiu H, Chu T, Cheng Y, et al. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. *PLoS ONE.* 2015; 10(11): e0142930.
3. Ricther L, Vujic I, Sesti A, et al. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. *JDDG.* 2016;309-317.
4. Deepak P, Loftus EV. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. *Drug Des Devel Ther.* 2016;3685–3698.
5. MICROMEDEX®SOLUTIONS Compendia. 2020. Ustekinumab.
6. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Ustekinumab.
7. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare.* 2016.
8. Torres T, Faria R. Ustekinumab: The “new kid on the block” in the treatment of psoriatic arthritis. *Drug Development Research.* 2015;428–431.
9. Stelara (ustekinumab) [package insert]. Horsham, PA. Janssen Biotech, Inc. 07/2020.
10. Lichtenstein G, Loftus E, Isaacs K, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2018;113:481–517.
11. Menter A, Gottlieb A, Feldman S, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol.* 2018;58(5):826-850.
12. Menter A, Strober B, Kaplan D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019;80:1029-1072.
13. Rubin D, Snanthakrishnan A, Siegel C, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol.* 2019;114:384-413.
14. Hanauer S, Sandborn W, Feagan B, et al. IM-UNITE: Three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease. *J Crohns Colitis.* 2020;14(1):23-32.
15. Adedokun O, Xu Z, Marano C, et al. Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis. *Clin Gastroenterol and hepatol.* 2020;18(10):2244-2255.e9.
16. Ustekinumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 2020.
17. Ustekinumab. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.